Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

ClinicalTrials.gov 24,857 recruiting now free trial finder

Find a clinical trial that's recruiting now

Search 24,857 actively recruiting US clinical trials by condition, drug, or state, each entry links straight to its NIH ClinicalTrials.gov record so you can check eligibility and contact the study team.

24,857
trials recruiting now
14%
of all US trials open to enrollment
52
states with recruiting sites

A trial is listed as recruiting when its sponsor has marked it open to new participants on the public registry. Type a condition or drug name (for example, "breast cancer" or "pembrolizumab") to narrow the list, and add a state to find studies with a site near you. Results are ordered with the most relevant recruiting studies first; each card shows the study phase and enrollment target, and opens the full record, including eligibility criteria and contact details, on ClinicalTrials.gov.

Showing the 40 largest recruiting trials by target enrollment in Alaska. Use the search field to focus on a condition or drug.

Recruiting 75,000 participants

Project: Every Child for Younger Patients With Cancer

Children's Oncology Group

NCT02402244

Recruiting 30,000 participants

MammaPrint, BluePrint, and Full-genome Data Linked With Clinical Data to Evaluate New Gene EXpression Profiles

Agendia

NCT03053193

Recruiting 20,000 participants

Product Performance Report: Evaluate Long-term Reliability & Performance of Medtronic Marketed Cardiac Therapy Products

Medtronic

NCT00271180

Recruiting NA 17,800 participants

Machine Learning Prediction of Possible Central Line Associated Blood Stream Infections and Rate of Reduction

Swedish Medical Center

NCT07108660

Recruiting Phase 2 10,000 participants

Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer

SWOG Cancer Research Network

NCT03851445

Recruiting NA 9,500 participants

Five or Ten Year Colonoscopy for 1-2 Non-Advanced Adenomatous Polyps

NRG Oncology

NCT05080673

Recruiting NA 8,060 participants

School Screening and Telemedicine Specialty Referral to Address Childhood Hearing Loss in Rural Alaska

University of Arkansas

NCT05593484

Recruiting 8,000 participants

MILD® Percutaneous Image-Guided Lumbar Decompression: A Medicare Claims Study

Stryker Instruments

NCT03072927

Recruiting Phase 3 5,951 participants

Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy

Children's Oncology Group

NCT03959085

Recruiting Phase 3 4,300 participants

A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy

AstraZeneca

NCT05774951

Recruiting 4,000 participants

The Alaska Oculocardiac Reflex Study

Alaska Blind Child Discovery

NCT04353960

Recruiting Phase 3 3,960 participants

Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25

NRG Oncology

NCT05879926

Recruiting Phase 3 3,680 participants

Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer

National Cancer Institute (NCI)

NCT06058377

Recruiting Phase 2 2,900 participants

Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

National Cancer Institute (NCI)

NCT05564377

Recruiting Phase 3 2,400 participants

Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer

SWOG Cancer Research Network

NCT05929768

Recruiting Phase 3 2,140 participants

Regional Radiotherapy in Biomarker Low-Risk Node Positive and T3N0 Breast Cancer

Canadian Cancer Trials Group

NCT03488693

Recruiting 2,000 participants

Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics

Wake Forest University Health Sciences

NCT06418204

Recruiting 2,000 participants

Evaluating the Impact of Social and Genetic Factors on Outcomes in Adolescent and Young Adult Cancer Survivors

ECOG-ACRIN Cancer Research Group

NCT06002828

Recruiting 2,000 participants

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

Alliance for Clinical Trials in Oncology

NCT05334069

Recruiting NA 1,956 participants

A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer

NRG Oncology

NCT04251052

Recruiting Phase 3 1,875 participants

A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab

National Cancer Institute (NCI)

NCT05675410

Recruiting 1,800 participants

EXActDNA-003 / NSABP B-64: Study of Molecular Residual Disease Detection in Breast Cancer (MRD)

Exact Sciences Corporation

NCT06401421

Recruiting Phase 3 1,780 participants

Active Surveillance, Bleomycin, Etoposide, Carboplatin or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell Tumors

Children's Oncology Group

NCT03067181

Recruiting Phase 3 1,755 participants

The AIRTIVITY™ Study: A Study to Find Out Whether BI 1291583 Helps People With Bronchiectasis

Boehringer Ingelheim

NCT06872892

Recruiting Phase 3 1,656 participants

A Study Using Risk Factors to Determine Treatment for Children With Favorable Histology Wilms Tumors (FHWT)

Children's Oncology Group

NCT06401330

Recruiting 1,600 participants

A Prospective Registry Study to Assess Real-world Patient Characteristics, Treatment Patterns, and Longitudinal Outcomes in Patients Receiving Mavacamten and Other Treatments for Symptomatic Obstructive Hypertrophic Cardiomyopathy (Obstructive-HCM)

Bristol-Myers Squibb

NCT05489705

Recruiting Phase 3 1,450 participants

Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial

ECOG-ACRIN Cancer Research Group

NCT04566328

Recruiting Phase 3 1,400 participants

Phase IIIb Study of Ribociclib + ET in Early Breast Cancer

Novartis Pharmaceuticals

NCT05827081

Recruiting NA 1,312 participants

Family-Based Financial Incentives Intervention for Smoking Cessation

Mayo Clinic

NCT06556433

Recruiting Phase 3 1,295 participants

Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab

Alliance for Clinical Trials in Oncology

NCT05812807

Recruiting Phase 2 1,260 participants

Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer

BioNTech SE

NCT06712316

Recruiting Phase 3 1,210 participants

Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])

National Cancer Institute (NCI)

NCT04267848

Recruiting Phase 3 1,123 participants

A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)

Merck Sharp & Dohme

NCT06952504

Recruiting NA 1,075 participants

Efficacy-Implementation Study for PC CARES in Rural Alaska

University of Michigan

NCT06658808

Recruiting Phase 3 1,057 participants

Evaluating Whether an Educational Website Called Current Together After Cancer (CTAC) Improves Follow-up Care for Colorectal Cancer Survivors

SWOG Cancer Research Network

NCT07018869

Recruiting Phase 3 1,018 participants

A Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular Lymphoma Patients

AstraZeneca

NCT06549595

Recruiting Phase 1 1,006 participants

A Study of Sigvotatug Vedotin in Advanced Solid Tumors

Seagen, a wholly owned subsidiary of Pfizer

NCT04389632

Recruiting Phase 1 960 participants

The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study

PedAL BCU

NCT04726241

Recruiting NA 947 participants

The TELENEO Trial: A Multicenter Trial of Telemedicine for Advanced Neonatal Resuscitations in Community Hospitals

Mayo Clinic

NCT06087224

Recruiting Phase 3 920 participants

A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)

Eli Lilly and Company

NCT07174336

Source: ClinicalTrials.gov (NIH/NLM) ClinicalTrials.gov AACT registry · 2026 Recruiting status is reported by each study's sponsor and mirrored from the public registry. Always confirm current eligibility and status on ClinicalTrials.gov before contacting a study.

Verify with NIH →